Country: Malaysia
Language: English
Source: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)
ENROFLOXACIN
Hipra Malaysia Sdn Bhd
ENROFLOXACIN
100.00 mcg/mL
Laboratorios Hipra, S.A.
705356-02.1 02-18 HIPRALONA ENRO-I Enrofloxacin 50 mg/ml solution for injection for cattle and swine COMPOSITION PER ML: Enrofloxacin 50 mg. Clear solution slightly yellowish. Enrofloxacin is a broad-spectrum antibacterial, belonging to the fluoroquinolone family. It acts by inhibiting DNA replication, by inhibiting bacterial DNAgyrase and topoisomerase IV. It is bactericidal at very low concentrations. It is active against Gram-negative bacteria (_Escherichia _ _coli, Salmonella sp, Pasteurella sp, Klebsiella sp, _ _Haemophilus _ _sp, _ _Pseudomonas _ _sp_), some Grampositive bacteria and _Mycoplasma_. It is rapidly absorbed after administration by subcutaneous route, reaching maximum concentrations between 30 minutes and 2 hours after injection. It presents a high volume of distribution and an optimum tissue penetration, reaching very high tissue concentrations. The serum and tissue concentrations of enroflaxacin are much higher than the MIC/MBC of most sensitive microorganisms; therapeutically effective levels are maintained for 24 hours. ADMINISTRATION ROUTE: Swine: Intramuscular Injection. Bovine: Subcutaneous Injection. DOSAGE: Cattle: 2.5 mg enrofloxacin per kg bodyweight (0.5 ml/10 kg) daily for 3 days. This rate may be doubled to 5 mg enrofloxacin per kg bodyweight (1.0 ml/10 kg) for 5 days for salmonellosis and complicated respiratory diseases. Not more than 10 ml should be administered at the one subcutaneous injection site. Pigs: 2.5 mg enrofloxacin per kg bodyweight (0.5 ml/10 kg) daily for 3 days. This rate may be doubled to 5 mg enrofloxacin per kg bodyweight (1.0 ml/10 kg) for 5 days for salmonellosis and complicated respiratory diseases. Not more than 2.5 ml should be administered at the one intramuscular site. INDICATIONS: Cattle: Diseases of the respiratory and alimentary tract of bacterial or mycoplasmalnorigin (e.g. pasteurellosis, mycoplasmosis, coli-bacillosis, coli-septicaemia and salmonellosis) and secondary bacterial infections subsequent to viral conditions (e.g. viral pneumonia), where Read the complete document